Table 2.
Characteristics of included experimental studies (LAD- Left anterior descending coronary artery; KO- Knockout; AAR- Area at risk, CSA- Cross-sectional area; WT- Wildtype; IV- Intravenous, IP- Intraperitoneally).
| Studies | Animal model | Age (wks) | weight | MI Surgical procedure | Duration of MI | Dosage/Method of administration | Outcome measures |
|---|---|---|---|---|---|---|---|
| Jing et al. 2019 [15] | IL-6 KO Mice | 12–16 | - | LAD | 28 days | Survival rate, echocardiographic outcomes, Fibrosis | |
| Fuchs et al.2003 [16] | IL-6 KO Mice | 11–14 | 25–30g | LAD | 6 weeks | Survival rate, infarct size, AAR, myocyte CSA, echocardiography measurements | |
| Tang et al.2018 [17] | IL-6 KO Mice | - | Neonatal mice | apical resection | 4 weeks | Echocardiographic measurements, fibrosis | |
| Muller et al.2014 [18] | WT Mice | 16-18 | - | LAD | 72h and 3 weeks for ventricular function, 24h for infarct size and AAR | Anti-IL6 Ab (250ug/mouse)/IP dosage | Survival rate, infarct size, myocyte CSA, echocardiographic measurement |
| Jong et al.2016 [19] | IL-6 KO Mice | 8–10 | - | surgical ischemia in closed-chest | 1h ischemia and 0,1/2, 3 and 24h reperfusion | Infarct size, AAR and Fibrosis | |
| Bonda et al.2014 [20] | IL-6 KO Mice | 12-14 | - | LAD | 8 weeks | Echocardiographic measurements | |
| Dawn et al.2004 [21] | IL-6 KO Mice | 12–26 | 25–35g | coronary occlusion | 30-min coronary occlusion followed by 24 h of reperfusion | Infarct size and AAR | |
| Hartman et al.2016 [22] | WT Mice | 8 | 26–29 g | LAD | 28 Days | Anti-IL-6R Ab∗ (MR16-1 2mg/mouse)/IV dosage | Infarct size, AAR, Fibrosis, hemodynamic measurements |
| Kobara et al.2010 [23] | WT Mice | 8–12 | 25–30g | LAD | 7 Days and 28 Days after surgery | Anti-IL-6R Ab# (MR16-1 500ug/body)/IP dosage | Survival rate, infarct size, AAR, Fibrosis, myocyte CSA, echocardiography measurements |
| Kaminski et al.2009 [24] | IL-6 KO Mice | 12–16 | 27–29g | LAD | 30 min of regional reversible myocardial ischemia | Infarct size and AAR | |
| Hilfiker-Kleiner et al.2010 [25] | gp130 KO mice | 12-16 | - | LAD | 2 weeks | Echocardiographic measurements, Myocyte CSA | |
| George et al.2021 [26] | Male Sprague-Dawley rats | 7-8 | 200–250g | LAD for 50min | 50 min of ischemia, followed by reperfusion | Anti–IL-6-Ab (0.1 μg/mg)/IP sgp130Fc (0.5 μg/mg)/IV | Infarct size, AAR, cardiac magnetic resonance imaging |
(∗ indicates MR16-1 dosage (anti-mice IL-6R antibody) of 2mg/mouse intravenously; # represents MR16-1 dosage (rat anti-mouse IL-6R monoclonal antibody) of 500ug/body intraperitoneally).